The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and radiological features of advanced RET-rearranged lung cancer.
 
Masafumi Saiki
No Relationships to Disclose
 
Fumiyoshi Ohyanagi
No Relationships to Disclose
 
Ryo Ariyasu
No Relationships to Disclose
 
Junji Koyama
No Relationships to Disclose
 
Tomoaki Sonoda
No Relationships to Disclose
 
Yosuke Kawashima
No Relationships to Disclose
 
Natsuki Takano
No Relationships to Disclose
 
Tomoyo Oguri
No Relationships to Disclose
 
Shingo Nishikawa
No Relationships to Disclose
 
Satoru Kitazono
No Relationships to Disclose
 
Noriko Yanagitani
Consulting or Advisory Role - Chugai Pharma
 
Atsushi Horiike
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma (Inst); MSD Oncology (Inst); Quintiles (Inst)
 
Hironori Ninomiya
No Relationships to Disclose
 
Kengo Takeuchi
Honoraria - Chugai Pharma; Kirin Pharmaceuticals; Meiji Seika Kaisha; Takeda
Consulting or Advisory Role - Chugai Pharma; Nichirei
Patents, Royalties, Other Intellectual Property - Nichirei
 
Yuichi Ishikawa
Honoraria - Bristol-Myers Squibb; Lilly; Ministry of Environment, Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Sanofi
Consulting or Advisory Role - Fujirebio Diagnostics
Research Funding - Daiichi Sankyo (Inst)
 
Katsunori Oikado
No Relationships to Disclose
 
Makoto Nishio
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)